BrainsWay’s New Indication Is Aimed at OCD Patients
The Jerusalem, Israel-based company said this FDA clearance represents the first ever non-invasive medical device clearance for the treatment of OCD.
August 20, 2018
About 3% of the U.S. population suffers from obsessive compulsive disorder (OCD), according to an article published on HealthyPlace.com Statistics also show that one in every 200 children suffers from the disorder.
BrainsWay is looking to use its technology to help treat the illness, which is described as a disorder of the brain that adversely affects behavior and causes intense anxiety in those with the condition. The Jerusalem, Israel-based company recently received De Novo clearance from FDA for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of OCD in adults.
BrainsWay said this clearance represents the first ever non-invasive medical device clearance for the treatment of OCD, and the second indication granted for BrainsWay Deep TMS, which was cleared in 2013 for the treatment of treatment-resistant major depressive disorder (MDD). BrainsWay intends to start installing BrainsWay OCD immediately as an upgrade of its current systems and as part of new installations. Clinics that have or will have a Deep TMS systems can now treat MDD and OCD patients.